title: Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
abstract: In the National Institutes of Neurologic Disorders and Stroke (NINDS) recombinant tissue plasminogen activator (rt-PA) stroke trial, the primary adverse events monitored were intracranial hemorrhage (ICH), systemic bleeding, death and new stroke. Nurses caring for the study patients noted these adverse events and other complications. In addition to what is known about acute ischemic stroke (AIS), the NINDS trial provides further information for optimal care of this specific group of patients. The complications found in this trial require expert nursing care to monitor, prevent and intervene, making clinical decisions relevant to the patients needs. The critical decision-making process must be grounded in knowledge of acute stroke physiology and thrombolysis.
authors.affiliation: University of Pittsburgh Medical Center, Stroke Institute, Pennsylvania 15213, USA.
authors.forename: C
authors.initials: C
authors.lastname: Barch
authors.forename: J
authors.initials: J
authors.lastname: Spilker
authors.forename: P
authors.initials: P
authors.lastname: Bratina
authors.forename: K
authors.initials: K
authors.lastname: Rapp
authors.forename: S
authors.initials: S
authors.lastname: Daley
authors.forename: R
authors.initials: R
authors.lastname: Donnarumma
authors.forename: S
authors.initials: S
authors.lastname: Sailor
authors.forename: J
authors.initials: J
authors.lastname: Braimah
authors.forename: G
authors.initials: G
authors.lastname: Kongable
mesh_terms: D000208:Acute Disease; D000465:Algorithms; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000451:nursing*; D019091:Critical Pathways; D016903:Drug Monitoring / Q000451:nursing*; D006801:Humans; D009460:Neurologic Examination / Q000451:nursing; D009730:Nursing Assessment; D010960:Plasminogen Activators / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator